Cargando…

Neuroleptic malignant syndrome associated with second-generation antipsychotics (SGA): An analysis of reported cases in eudravigilance database, 2017-2020

INTRODUCTION: Antipsychotic drugs are the cornerstone of the pharmacological treatment of psychotic disorders; however, even with Second-generation antipsychotics (SGA), adverse effects continue to be extremely accentuated and the treatment effectiveness is compromised by low adherence of the patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, A., Mignano, A., Viseu, I., Rodrigues, L., Herdeiro, T., Silva, L., Afreixo, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480265/ http://dx.doi.org/10.1192/j.eurpsy.2021.2151

Ejemplares similares

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis
por: Belvederi Murri, Martino, et al.
Publicado: (2015)

Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose
por: Korchia, Théo, et al.
Publicado: (2018)

Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription
por: Reilly, Thomas J, et al.
Publicado: (2017)

Antipsychotic-induced catatonia and neuroleptic malignant syndrome: the dark side of the moon
por: Hirjak, Dusan, et al.
Publicado: (2021)

Neuroleptic Malignant Syndrome with Low Dose Lithium, Without Concomitant Antipsychotics
por: Ramadas, Smitha, et al.
Publicado: (2022)

The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome
por: Kyotani, Yoji, et al.
Publicado: (2023)

Severe Recurrence of Neuroleptic Malignant Syndrome: Usefulness of Dexmedetomidine for Antipsychotic Withdrawal
por: Maeda, Keisuke, et al.
Publicado: (2023)

An Unusual Case of Neuroleptic Malignant Syndrome on a Stable Dose of Antipsychotic
por: Sanger, Emily, et al.
Publicado: (2023)

A Case of Catatonia and Neuroleptic Malignant Syndrome Probably Associated with Antipsychotic in Korea
por: Choi, Ho-Dong, et al.
Publicado: (2011)

Two cases of neuroleptic malignant syndrome in elderly patients taking atypical antipsychotics
por: Feng, Yuhui, et al.
Publicado: (2013)

Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene
por: Ngo, Vivian, et al.
Publicado: (2019)

CHALLENGE WITH ATYPICAL ANTIPSYCHOTIC DRUGS IN RISPERIDONE INDUCED NEUROLEPTIC MALIGNANT SYNDROME: A CASE REPORT
por: Mendhekar, D.N., et al.
Publicado: (2002)

Rhabdomyolysis and Neuroleptic Malignant Syndrome Associated with Very Low-dose Antipsychotics in Children and Adolescent
por: Park, Jong-Il, et al.
Publicado: (2019)

Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association
por: Sarkar, Siddharth, et al.
Publicado: (2017)

Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system
por: Hirofuji, Sakiko, et al.
Publicado: (2023)

NEUROLEPTIC MALIGNANT SYNDROME
por: Jayesh, Kanabar
Publicado: (1997)

Neuroleptic malignant syndrome
por: Rajamani, Bino, et al.
Publicado: (2016)

Neuroleptic malignant syndrome
por: Tan, Carolyn Michelle, et al.
Publicado: (2023)

Neuroleptic Malignant Syndrome After Re-introduction of Atypical Antipsychotics in a COVID-19 Patient
por: Espiridion, Eduardo D, et al.
Publicado: (2021)

Neuroleptic Malignant Syndrome due to Atypical Antipsychotics in a COVID-19-positive Pregnant Woman
por: Burad, Jyoti, et al.
Publicado: (2021)

A case of malignant hyperthermia that was difficult to be differentiated from oral antipsychotic polypharmacy-associated neuroleptic malignant syndrome
por: Hara, Yoshiki, et al.
Publicado: (2016)

Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam
por: Yacoub, Adeeb, et al.
Publicado: (2006)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
por: Fontaine, Jennifer, et al.
Publicado: (2022)

Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report
por: Langan, Julie, et al.
Publicado: (2012)

INCREASED RISK OF OCCURRENCE OF NEUROLEPTIC MALIGNANT SYNDROME ON COMBINED TREATMENT WITH LITHIUM AND NEUROLEPTIC
por: Alexander, P. John, et al.
Publicado: (1997)

Malignant Catatonia Versus Neuroleptic Malignant Syndrome
por: Desai, Saral, et al.
Publicado: (2021)

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection
por: Postigo, Rodrigo, et al.
Publicado: (2018)

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018
por: Popiołek, Iwona, et al.
Publicado: (2019)

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports
por: Baan, Esmé J., et al.
Publicado: (2019)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database
por: Jesus, Mafalda, et al.
Publicado: (2023)

Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023)

Risk Factors in Neuroleptic Malignant Syndrome
por: Gupta, Vinay, et al.
Publicado: (2003)

Resolution of symptoms in neuroleptic malignant syndrome
por: Pereira, Yvonne D.S., et al.
Publicado: (2010)

Olanzapine induced neuroleptic malignant syndrome
por: Patra, Bichitra Nanda, et al.
Publicado: (2013)

Olanzapine-Induced Neuroleptic Malignant Syndrome
por: Hosseini, Seyedhamze, et al.
Publicado: (2017)

Olanzapine-induced Neuroleptic Malignant Syndrome
por: Saha, Pradeep Kumar, et al.
Publicado: (2017)

Clozapine Induced Neuroleptic Malignant Syndrome
por: Jo, Yong Suk, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qnkubvg14fdru6hncbkqa13f26